NCT04895748 2026-03-03DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other MalignanciesNovartisPhase 1 Terminated40 enrolled
NCT00911729 2013-06-10Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and ParagangliomaMolecular Insight Pharmaceuticals, Inc.Terminated24 enrolled